EMA Lifts Novartis’s LCZ696 Prospects With Fast Track Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
Fast Track designation in Europe brightens outlook for the novel two-in-one pill that Novartis says could transform treatment for heart failure and which is already in the midst of a rolling submission in the U.S.